Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Merck & Co. patent describes IRAK-4 inhibitors

April 19, 2016

Scientists steer ligand bias between beta-arrestin 2 and G protein pathway for biased CXCR3 agonists

April 19, 2016

FDA grants approval for phase II trial on Resunab

April 13, 2016

Merck & Co. patents IRAK-4 inhibitors

April 13, 2016

FDA approves infliximab biosimilar Inflectra in the U.S.

April 6, 2016

Positive topline results presented from the first phase III trial of tofacitinib in PsA

April 6, 2016

Samsung Bioepis' infliximab biosimilar receives positive opinion in E.U.

April 4, 2016

Janssen discontinues phase III development of fulranumab for osteoarthritis pain

April 4, 2016

Anika Therapeutics receives CE Mark approval for Cingal

March 30, 2016

Samumed divulges Wnt signaling inhibitors

March 23, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis
BioWorld Science
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...